Legend Biotech Corporation, a biotechnology company focused on cell therapies for oncology, reports strong financial performance driven by its flagship CAR-T therapy Carvykti, which achieved 74.75% year-over-year revenue growth and recorded $369 million in Q1 2025 sales. Carvykti has demonstrated impressive long-term remission results, with a median overall survival of 60.6 months and potential curative effects in 33% of late-line multiple myeloma patients. The therapy is gaining traction in earlier lines of treatment, with over 50% of U.S. uptake occurring in early lines, and analysts project sales to reach $1.9 billion in 2025. The company has secured FDA approval for later lines of treatment and EMA approval with a statistically significant survival benefit, supporting expansion into ex-EU markets. Legend Biotech is expanding manufacturing capacity to 10,000 treatment slots annually through partnerships with Novartis and Johnson & Johnson and in-house facilities. The company also has a diverse pipeline including LB1908 and LB2102 in Phase I trials for gastric/esophageal and small cell lung cancer. Despite strong growth, it faces competition from therapies like Anito-cel and emerging alternatives such as bispecific antibodies and allogeneic CAR-Ts. Analysts remain bullish with price targets ranging from $71 to $94, though risks include increased competition, manufacturing complexity, and regulatory challenges.

HTF Market Intelligence has released a comprehensive 143-page study on the global genetic engineering market, projecting it will grow from $10 billion in 2025 to $28 billion by 2032 at a compound annual growth rate (CAGR) of 14.2%. The market is segmented by type—including gene therapy, CRISPR gene editing, genetically modified crops, and synthetic biology—and by application such as medicine, agriculture, and industrial biotech. Key players include CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, Sangamo Therapeutics, and others. North America is the dominant region, while Asia-Pacific is the fastest-growing. Market drivers include advances in genome editing, demand for sustainable agriculture, and evolving regulatory frameworks. Challenges include ethical concerns, high costs, intellectual property disputes, and environmental risks. The report includes detailed analysis of market segments, competitive landscape, five forces, and PESTLE factors across global regions.

Cantor Fitzgerald has reiterated its stock rating for Gilead Sciences at Overweight, citing strong growth potential in the global immunology market. The market was valued at $110.1 billion in 2023 and is projected to reach $204.0 billion by 2033, growing at a CAGR of 6.3%. Key drivers include rising prevalence of chronic diseases, increased awareness of immune-related conditions, and higher R&D investment. Regulatory constraints remain a challenge. Recent developments include Gilead's exclusive license agreement with Xilio Therapeutics for the tumor-activated IL-12 program XTX301, and an expanded collaboration with Arcus Biosciences to include inflammatory diseases. Biopharmaceuticals and autoimmune disease segments dominate market share, with hospitals and clinics as the primary end users. North America is expected to lead the market by 2033, followed by rapid growth in Asia-Pacific and LAMEA. Major market players include AbbVie, Johnson & Johnson, Pfizer, Novartis, Merck, Bristol-Myers Squibb, Amgen, Eli Lilly, and Gilead Sciences.

The Visceral Leishmaniasis Market 2025 Forecast to 2032 report provides a comprehensive analysis of the global market, including economic trends, competitive landscape, supply chain dynamics, and regional growth prospects. The study segments the market by drug type, administration route, dosage form, disease stage, age group, distribution channel, and end user. It profiles key players such as Gilead Sciences, Profounda Inc., Novartis AG, GSK Plc, Zydus Lifesciences Limited, and MOLOGEN AG, and evaluates market drivers, restraints, technological advancements, and regulatory factors. The report offers forward-looking projections on market size, growth potential, and investment opportunities across regions including North America, Latin America, Western Europe, Eastern Europe, Asia Pacific, and the Middle East and Africa, aiming to support strategic decision-making for stakeholders in healthcare and pharmaceuticals.

Worldwide Market Reports has released an analysis of the Blockbuster Oncology Brands Market, highlighting the industry's shift toward next-generation cancer therapeutics with significant revenue potential. The report identifies key drivers such as rising global cancer incidence, breakthrough immuno-oncology treatments, and accelerated regulatory approvals from the FDA and EMA. Market growth is fueled by precision oncology, combination therapies (especially immunotherapy with chemotherapy), and biomarker-driven patient targeting. Major pharmaceutical companies including Roche, Bristol Myers Squibb, Merck, Novartis, AstraZeneca, Pfizer, Johnson & Johnson (Janssen), Gilead, Takeda, and Eli Lilly are leading the market. North America holds the largest market share, while Asia-Pacific is the fastest-growing region. Key trends include expansion into rare cancers, tumor-agnostic therapies, AI in clinical trial design, and improved patient adherence through digital tools.